FINANCE/FUNDING ARTICLES

• Dealmakers In Life Sciences: More Active, More Creative

  “Our belief is that the underlying strength of the life sciences sector will continue to promote dealmaking activity going forward, continuing its outperformance of other sectors.”

• The Evolving Payer Focus On Prevalence In Rare Diseases

  A recent analysis of trends in payer decisions related to reimbursement indicates that payers are looking at a range of issues, including disease prevalence, with new levels of scrutiny and are working to rein in pricing of many rare disease treatments.

• How To Overcome The Challenge Of Valuing A Biotech

  Because of the unknowns around revenue streams, biotech valuation may appear to be more guesswork than science. However, common valuation methods can help account for some of the product-line uncertainty.

• From Medtech CEO To Impact Investor — Not Your Typical Retirement Plan

  Tim Ring, former chairman and CEO of C.R. Bard, shares how he and his spouse retired to build TEAMFund, a $30 million impact investment fund focused on having a positive impact on health in some of the most resource constrained areas of the world.

• 7 Elements Of A Successful Biotech Funding Plan

  Life sciences companies seeking to raise capital or form early partnerships with strategic players often make avoidable mistakes. Here are some tips that can increase your probability of a successful transaction.

• Nasdaq Listing Requirements Launch A Reverse Listings Revamp

  The SEC’s new changes to Nasdaq’s initial listing standards do have the potential to place substantial additional burdens on smaller companies seeking to list through reverse listings.

• The Many Shades Of VC/Repeat Entrepreneur Relationships

  Repeat entrepreneur is a term you might hear often in the context of life sciences company creation and investment, so we wanted to take a moment to unpack it and offer lessons for those on either side of the table.

• Tackling Cell & Gene Therapy Financing & Manufacturing Challenges

  As interest in the cell and gene market continues to heat up, the sector’s manufacturing and finance challenges have become top priorities.

• Making Sense Of New Accounting And Financial Reporting Changes

  A summary of some key sections of version 10 of Deloitte’s Life Sciences Accounting And Financial Reporting Update—Including Interpretive Guidance.

• The Rollercoaster Ride Of A Biotech CEO

  Sam Cobb, managing director and CEO of Australian biotech AdAlta, talks about how the company has struggled to procure funding over the years and the strategies they employed to finally get listed on the Australian Securities Exchange.